KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Teva Pharmaceutical Industries (TEVA) Short-Term Debt repayments (2020 - 2023)

Teva Pharmaceutical Industries (TEVA) has disclosed Short-Term Debt repayments for 3 consecutive years, with $500.0 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Short-Term Debt repayments changed N/A year-over-year to $500.0 million, compared with a TTM value of $500.0 million through Dec 2024, down 50.0%, and an annual FY2023 reading of $700.0 million, changed N/A over the prior year.
  • Short-Term Debt repayments was $500.0 million for Q4 2023 at Teva Pharmaceutical Industries, roughly flat from $500.0 million in the prior quarter.
  • Across five years, Short-Term Debt repayments topped out at $500.0 million in Q4 2021 and bottomed at $443.0 million in Q4 2020.
  • Average Short-Term Debt repayments over 3 years is $481.0 million, with a median of $500.0 million recorded in 2021.
  • Peak annual rise in Short-Term Debt repayments hit 12.87% in 2021, while the deepest fall reached 12.87% in 2021.
  • Year by year, Short-Term Debt repayments stood at $443.0 million in 2020, then rose by 12.87% to $500.0 million in 2021, then changed by 0.0% to $500.0 million in 2023.
  • Business Quant data shows Short-Term Debt repayments for TEVA at $500.0 million in Q4 2023, $500.0 million in Q4 2021, and $443.0 million in Q4 2020.